Summit Therapeutics
SMMT
58 hedge funds and large institutions have $30.4M invested in Summit Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 8 closing their positions.
346% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $235K
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
41% more funds holding
Funds holding: 41 → 58 (+17)
0.15% more ownership
Funds ownership: 11.21% → 11.37% (+0.15%)
44% less capital invested
Capital invested by funds: $54.6M → $30.4M (-$24.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$5.27M |
| 2 |
BlackRock
New York
|
+$2.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.17M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.68M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$878K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$549K |
| 4 |
Goldman Sachs
New York
|
-$301K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$220K |
SMMT Hedge Fund Activity: Q2 2021 in Review
58 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2021, worth a combined $30.4M — down 44% from $54.6M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SMMT positions and 8 closed out — a net gain of 17 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $5.27M. The largest seller was Millennium Management, exiting entirely with an estimated $2.03M sold.
- 58 institutional investors held Summit Therapeutics (SMMT) as of Q2 2021, up from 41 in Q1 2021.
- Funds reported $30.4M of Summit Therapeutics stock for Q2 2021, down 44% quarter-over-quarter.
- 25 funds opened new Summit Therapeutics positions in Q2 2021 and 8 closed out, a net change of +17 holders.
- The largest Summit Therapeutics buyer in Q2 2021 was Polar Capital Holdings, an estimated $5.27M added.
- The largest Summit Therapeutics seller in Q2 2021 was Millennium Management, an estimated $2.03M sold.
Based on aggregated 13F filings for Q2 2021.